By InvitationPhase 4

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

United States30 participantsStarted 2025-05-01

Plain-language summary

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Who can participate

Age range

46 Years – 60 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy) * Age 46-60 years old * BMI ≥ 30 kg/m2. Exclusion Criteria: * Past or current use of menopausal hormone therapy * Early or premature menopause * History of chemically induced menopause * Impaired renal function (GFR ≤29) * Thyroid-stimulating hormone ≥7 with low free T4 * Diabetes * Cardiovascular disease * Elevated blood pressure (\>170/\>95) * Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease * \>5% change in weight during the 3 months prior to screening * Other anti-obesity medication use within the past 3 months * History of bariatric surgery * History of malignant neoplasms within the past 5 years prior to screening * Current use of supplements known to affect weight * Personal or family history of medullary thyroid cancer. * Wheelchair bound * Vision loss

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Physical Function Measure: Short Physical Performance Battery (SPPB) score.

Timeframe: 24 weeks

Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat

Timeframe: 24 weeks

Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)

Timeframe: 24 weeks

Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)

Timeframe: 24 weeks

Physical Function Measure: Six-Minute Walk Test (6MWT)

Timeframe: 24 weeks

Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer

Timeframe: 24 weeks

Physical Function Measure: Short Form-12 (SF-12) Health Survey

Trial details

NCT IDNCT07057310

SponsorMayo Clinic

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Obesity trials

Plain-language summary

Who can participate

Age range

46 Years – 60 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Physical Function Measure: Short Physical Performance Battery (SPPB) score.

Timeframe: 24 weeks

Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat

Timeframe: 24 weeks

Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)

Timeframe: 24 weeks

Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)

Timeframe: 24 weeks

Physical Function Measure: Six-Minute Walk Test (6MWT)

Timeframe: 24 weeks

Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer

Timeframe: 24 weeks

Physical Function Measure: Short Form-12 (SF-12) Health Survey